Safe Delivery of Thrombolytic Treatment for Pulmonary Embolism Using ClotPro® Viscoelastic Tests

Inclusion Criteria: * Pulmonary embolism confirmed by CT angiography of the chest, and planned systemic thrombolysis, taking into account the following: * For indications based on circulatory collapse or circulatory instability that persists despite circulatory support, a fixed dose will be delivered, preferably with coagulation monitoring. The rtPA dose is 0.6 mg/kg over 15 minutes (with a maximum dose of 50 mg) for circulatory collapse, and 100 mg over 2 hours for circulatory instability that persists despite circulatory support. * Otherwise, a regime relevant to our study is followed in the following cases in the individuals randomised to the study treatment group: * Haemodynamic instability resolved through inotropic and/or vasopressor therapy, or * In the event of right heart strain confirmed by echocardiography, and elevated cardiac biomarker (hs Troponin-T/NT-proBNP) in a haemodynamically stable patient, the regime to be followed will be determined by the monitoring results. Exclusion criteria: * Failure to obtain informed consent from the patient (or from the closest relative of an incapacitated patient). * Coagulation tests included in the study protocol cannot be performed for any technical reason or samples cannot be collected. * Patients \<18 years of age at the onset of pulmonary embolism. * Pregnancy. * The following risk factors are known or currently present in the patient: * Haemorrhagic stroke at any time in the medical history * Major trauma or head…